Allosteric MEK1/2 inhibitor Refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A. Adjei, Jeffrey N. Miner, Dominik Mumberg, Karl Ziegelbauer, Arne Scholz

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint Dive into the research topics of 'Allosteric MEK1/2 inhibitor Refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences